Milk thistle extract, silibinin, reduces self-renewal of colorectal cancer stem cells

Colorectal cancer stem cells thrive in conditions of inflammation. A University of Colorado Cancer Center study presented today at the American Association for Cancer Research (AACR) Annual Meeting 2014 shows that the chemical silibinin, purified from milk thistle extract, affects cell signaling associated with inflammation and thus also the formation and survival of colorectal cancer stem cells.

"We have been deeply involved in this line of research that extends from silibinin to its chemopreventive properties in colorectal , and the current study takes another important step: we see both a likely chemopreventive mechanism and the result of this mechanism in animal models," says Sushil Kumar, PhD, postdoctoral fellow in the lab of Rajesh Agarwal, PhD, co-program leader of Cancer Prevention and Control at the CU Cancer Center and professor at the Skaggs School of Pharmacy and Pharmaceutical Sciences.

The group compared mice chemically treated to develop inflammation-dependent colorectal cancer given silibinin to a not given the drug. The results were clear: mice given silibinin showed less incidence of macroadenomas indicative of colorectal cancer, whereas nearly all mice in the control group developed the disease. In addition, in the silibinin group, Kumar and co-authors saw minimal colon inflammation, and minimal incidences of rectal bleeding and rectal prolapse as frequently observed in control mice.

"Results indicate that silibinin feeding indeed provided the mice with protective effect," Kumar says.

In addition to demonstrating chemopreventive benefit of silibinin, the current study adds to our understanding of how silibinin offers this benefit. The answer is found in colorectal (CSCs), which both replicate themselves and also give birth to the cells of themselves. In the presence of inflammation, CSCs both reproduce themselves (self-renewal) and produce colorectal cancer cells at a greater rate, and cells produced in these conditions are also signaled to survive at greater rates.

A key component of this expansion and survival signaling are chemicals called interleukins (IL-4 and-6), which are essential in increasing the number of CSCs and also regulate CSCs survival and function. Silibinin blocks this interleukin 4/6 signaling and so decreases levels of CSC self renewal -promoting mRNAs.

"We have been following this CSC signaling back to its source and we see now that silibinin affects the signaling of colorectal cancer very near their genesis," Kumar says.

It is notoriously difficult to gain approval for clinical trials of chemopreventive agents due to the necessity of treating many, healthy people to affect the very few who would otherwise have developed disease. But Kumar and colleagues hope to further refine the science of silibinin's chemopreventive properties while eventually exploring this chemical as a strategy for in a human population.

add to favorites email to friend print save as pdf

Related Stories

Controlling lung cancer in mice with milk thistle extract

Feb 16, 2011

(PhysOrg.com) -- Silibinin, a milk thistle extract, decreases tumor size in mice by inhibiting production of an enzyme that is overexpressed in certain types cancer, researchers at the University of Colorado Cancer Center ...

Milk thistle hits prostate cancer two ways

Apr 23, 2012

(Medical Xpress) -- Tumors are gluttons – in order to fuel their astounding growth rate they must gorge. A University of Colorado Cancer Center study recently published in the journal PLoS One pinpoints the compounds derived from milk thistle that best kill cancer cells ...

Milk thistle extract stops lung cancer in mice

Nov 15, 2011

Tissue with wound-like conditions allows tumors to grow and spread. In mouse lung cancer cells, treatment with silibinin, a major component of milk thistle, removed the molecular billboards that signal these wound-like conditions ...

Obesity primes the colon for cancer, study finds

Apr 01, 2014

Obesity, rather than diet, causes changes in the colon that may lead to colorectal cancer, according to a study in mice by the National Institutes of Health. The finding bolsters the recommendation that calorie control and ...

Recommended for you

Aspirin may lower the risk for aggressive prostate cancer

2 hours ago

Use of aspirin and/or other non-steroidal anti-inflammatory drugs (NSAIDs) was associated with a reduced risk for aggressive prostate cancer in men who had elevated prostate specific antigen (PSA) and a negative biopsy prior ...

User comments